Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases

Table 1 Patients’ demographic data and outcomes

Case	Gender	Age	Pathological diagnosis	Tumor location	Time to revision (m)	Follow-up time (m)	Revision reason	Complications	MSTS-93 score(1year)
1	M	19	Osteosarcoma	DF	45	52	Prosthesis breakage	None	26
2	M	66	Osteosarcoma	DF	126	48	Prosthesis breakage	None	27
3	M	16	Osteosarcoma	DF	32	60	Prosthesis bending	Wound complications	23
4	M	57	Osteosarcoma	DF	178	72	Proximal prosthesis break out	None	23
5	M	42	Osteosarcoma	DF	152	45	Screw breakage, LLD, pain	None	24
6	F	62	Chondrosarcoma	DF	162	72	Periprosthetic fracture	None	23
7	F	28	MBGCT	DF	96	70	MRSA infection	Infection without control, amputation	excluded
8	F	26	Osteosarcoma	DF	121	77	Prosthesis breakage	Infection, spacer-second revision	15
9	F	59	MBGCT	DF	123	155	Prosthesis wear and loosen	Prosthesis loosen, second revision	18
10	M	23	MBGCT	PT	132	77	Prosthesis loosen	Infection	16
11	F	45	Osteosarcoma	PT	106	55	Prosthesis loosen	None	26
12	M	22	Osteosarcoma	DF	61	66	Prosthesis loosen	Wound complications	18
13	M	23	Osteosarcoma	DF	66	65	Prosthesis breakage	None	23
14	F	44	MBGCT	DF	76	48	Prosthesis breakage	None	21
15	F	18	Chondrosarcoma	DF	145	27	Infection	None	18
16	M	16	Osteosarcoma	DF	38	36	Tumor recurrence	Pulmonary metastasis, die	16
17	F	23	MBGCT	PT	93	44	Infection	None	16
18	M	18	Ewing sarcoma	DF	84	47	Prosthesis breakage	None	21
19	M	20	Ewing sarcoma	DF	155	85	Prosthesis loosen	None	20
20	F	55	Chondrosarcoma	DF	35	93	Prosthesis breakage	None	24

LLD leg length discrepancy, MBGCT malignant bone giant cell tumor, DF distal femur, PT proximal tibia, MRSA methicillin-resistant Staphylococcus aureus

ISSN: 1477-7819